share_log

基石藥業-B：自願公告 - 基石藥業與Ewopharma就舒格利單抗在中東歐地區和瑞士達成戰略合作

CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE AND EWOPHARMA ENTER INTO STRATEGIC PARTNERSHIP FOR SUGEMALIMAB IN CENTRAL EASTERN EUROPE AND SWITZERLAND

Hong Kong Stock Exchange ·  May 27 00:00
Summary by Moomoo AI
基石藥業宣佈與Ewopharma達成戰略合作，將其研發的抗PD-L1單克隆抗體—舒格利單抗在中東歐地區及瑞士進行商業化。此合作涵蓋18個中東歐國家及瑞士，基石藥業將獲得最高5130萬美元的首付款及後續里程碑付款，並通過產品銷售獲得國際收入。舒格利單抗已在中國獲批五項適應症，並有望獲得歐洲藥品管理局（EMA）的批准。基石藥業將負責產品供應及品牌支持，而Ewopharma將負責定價、報銷、營銷和分銷。雙方領導均對此次合作表達了積極期待，認為能夠推動舒格利單抗在歐洲市場的臨床和商業價值，並為患者帶來新希望。此外，基石藥業正在與全球多個監管部門溝通，積極拓展全球開發與商業化合作。
基石藥業宣佈與Ewopharma達成戰略合作，將其研發的抗PD-L1單克隆抗體—舒格利單抗在中東歐地區及瑞士進行商業化。此合作涵蓋18個中東歐國家及瑞士，基石藥業將獲得最高5130萬美元的首付款及後續里程碑付款，並通過產品銷售獲得國際收入。舒格利單抗已在中國獲批五項適應症，並有望獲得歐洲藥品管理局（EMA）的批准。基石藥業將負責產品供應及品牌支持，而Ewopharma將負責定價、報銷、營銷和分銷。雙方領導均對此次合作表達了積極期待，認為能夠推動舒格利單抗在歐洲市場的臨床和商業價值，並為患者帶來新希望。此外，基石藥業正在與全球多個監管部門溝通，積極拓展全球開發與商業化合作。
Cornerstone Pharmaceuticals announced a strategic partnership with Ewopharma to commercialize its developed anti-PD-L1 monoclonal antibody — Sugarlicone Antibody in Middle East Europe and Switzerland. The partnership covers 18 Middle Eastern European countries and Switzerland, and Keystone Pharmaceuticals will receive up to $5130 million in initial and follow-up milestone payments and generate international revenue through product sales. Sugarlicone has been approved for five indications in China and is expected to receive approval from the European Medicines Agency (EMA). Keystone Pharmaceuticals will be responsible for product supply and brand support, while Ewopharma will be responsible for pricing, reimbursement, marketing and distribution. Both leaders expressed positive anticipation for the collaboration, which they believe will advance the clinical and commercial value of Sugarlicone in the European market and bring new hope to patients. IN ADDITION, PEBBLE PHARMACEUTICALS IS COMMUNICATING WITH MULTIPLE REGULATORY AGENCIES AROUND THE WORLD TO ACTIVELY PURSUE GLOBAL DEVELOPMENT AND COMMERCIALIZATION COOPERATION.
Cornerstone Pharmaceuticals announced a strategic partnership with Ewopharma to commercialize its developed anti-PD-L1 monoclonal antibody — Sugarlicone Antibody in Middle East Europe and Switzerland. The partnership covers 18 Middle Eastern European countries and Switzerland, and Keystone Pharmaceuticals will receive up to $5130 million in initial and follow-up milestone payments and generate international revenue through product sales. Sugarlicone has been approved for five indications in China and is expected to receive approval from the European Medicines Agency (EMA). Keystone Pharmaceuticals will be responsible for product supply and brand support, while Ewopharma will be responsible for pricing, reimbursement, marketing and distribution. Both leaders expressed positive anticipation for the collaboration, which they believe will advance the clinical and commercial value of Sugarlicone in the European market and bring new hope to patients. IN ADDITION, PEBBLE PHARMACEUTICALS IS COMMUNICATING WITH MULTIPLE REGULATORY AGENCIES AROUND THE WORLD TO ACTIVELY PURSUE GLOBAL DEVELOPMENT AND COMMERCIALIZATION COOPERATION.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more